About Applied DNA Sciences, Inc. - Common Stock (APDN)
Applied DNA Sciences is a biotechnology company that specializes in providing molecular solutions for supply chain security, product authenticity, and anti-counterfeiting measures. The company develops and employs proprietary DNA tagging technology to enable businesses to protect their products and verify their origins, enhancing transparency and trust in various industries, including pharmaceuticals, textiles, and consumer goods. Applied DNA Sciences also explores applications for its technology in fields such as biodefense and forensic science, making it a key player in the fight against counterfeit products and ensuring product integrity. Read More
Intrigued by the market activity in the middle of the day on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis.
The US market is yet to commence its session on Tuesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
Gainers SciSparc (NASDAQ: SPRC) shares increased by 28.2% to $5.68 during Monday's after-market session. The company's market cap stands at $2.2 million.
As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a biotechnology company focused on providing nucleic acid production solutions, today announced up to $58 million in commitments for a private investment in public equity (“PIPE”) offering led by institutional investors to initiate a digital asset treasury strategy based on BNB, the native cryptocurrency of the Binance blockchain ecosystem, the world’s largest cryptocurrency exchange1. Following the closing, the Company intends to begin deploying funds to acquire BNB, creating a gateway for institutional and retail investors to participate in the BNB blockchain and Binance ecosystem that powers millions of users and decentralized applications worldwide.
Gainers Enanta Pharma (NASDAQ: ENTA) stock rose 15.6% to $9.13 during Friday's after-market session. The market value of their outstanding shares is at $165.6 million.
As the regular session of the US market on Friday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
Intrigued by the market activity one hour before the close of the markets on Friday? Uncover the key winners and losers of today's session in our insightful analysis.
STONY BROOK, NY / ACCESS Newswire / September 23, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a biotechnology company focused on providing nucleic acid production solutions for the biopharmaceutical and diagnostics industries, announced that members of its business development and technical teams will be in attendance at upcoming industry conferences and present posters that underscore the Company's flexible nucleic acid production solutions designed to meet critical unmet needs for the manufacture of advanced biotherapeutics:
STONY BROOK, NY / ACCESS Newswire / August 14, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a biotechnology company focused on providing nucleic acid production solutions for the biopharmaceutical and diagnostics industries, today reported financial results for its third quarter of fiscal 2025 ended June 30, 2025. The Company's Form 10-Q for its fiscal third quarter can be viewed on the SEC Filings page of its Investor Relations website. The Company will not host a conference call to discuss these results. Applied DNA investor relations remains available for questions at investors@adnas.com .
STONY BROOK, NY / ACCESS Newswire / July 24, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in synthetic DNA manufacturing powered by scalable PCR platforms, today announced it received a seventh follow-on order valued at more than $600,000 for a multi-gram quantity of LineaDNA™. The follow-on order was placed by a global manufacturer of in vitro diagnostics (IVDs) under a long-standing supply agreement for the bulk manufacture of LineaDNA used as a functional component of a cancer diagnostic test. Deliveries are scheduled across four quarterly shipments beginning in the second quarter of fiscal 2026 (ending March 31, 2026).
As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
STONY BROOK, NY / ACCESS Newswire / July 7, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (the "Company"), a leader in PCR-based DNA technologies, today announced that on July 2, 2025, it received written notice (the "Compliance Notice") from The Nasdaq Stock Market LLC ("Nasdaq") informing the Company that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires that companies listed on the Nasdaq Capital Market maintain a minimum bid price of $1.00 per share, and that the Company is therefore in compliance with the Nasdaq Capital Market's listing requirements. Nasdaq also notified the Company in the Compliance Notice that the hearing before the Nasdaq Hearings Panel previously scheduled to take place on July 15, 2025, has been cancelled, and the Company's securities will continue to be listed and traded on The Nasdaq Capital Market.
